Leaflet VANTAS 50mg implant
Indicated for: central precocious puberty; prostate cancer
Route of administration: implantation
Substance: histreline (antineoplastic agent)
ATC: H01CA03 (Systemic hormonal preparations, excluding sex hormones and insulins | Hypothalamic hormones | Gonadotropin-releasing hormones)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of advanced prostate cancer and precocious puberty. It works by reducing the production of testosterone or estrogen, thereby suppressing the growth of hormone-sensitive tumors.
The medication is administered as a subcutaneous implant, as directed by a doctor. The implant gradually releases the drug over several months.
Side effects may include hot flashes, headache, decreased libido, or reactions at the implantation site. In rare cases, severe allergic reactions may occur.
Histrelin is not recommended for patients with hypersensitivity to this medication or pregnant women.
General data about VANTAS 50mg
- Substance: histreline
- Date of last drug list: 01-04-2014
- Commercial code: W58114001
- Concentration: 50mg
- Pharmaceutical form: implant
- Quantity: 1
- Product type: original
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).